Artículos por temáticas

The possible role of antioxidant vitamin C in Alzheimer's disease treatment and prevention

Heo JH, Hyon-Lee, Lee KM.

Am J Alzheimers Dis Other Demen. 2013 Mar;28(2):120-5. doi: 10.1177/1533317512473193. Epub 2013 Jan 9.

Memantine effects measured with the Relevant Outcome Scale for Alzheimer's disease in an open-label, single-arm, multicenter clinical study

Holthoff V, Ferris S, Gauthier S, Ihl R, Robert P, Winblad B, Sternberg K, Tennigkeit F; ROSA Study Group.

Int J Geriatr Psychiatry. 2013 Feb;28(2):164-72. doi: 10.1002/gps.3805. Epub 2012 Apr 11.

Effects of pharmacological agents, sleep deprivation, hypoxia and transcranial magnetic stimulation on electroencephalographic rhythms in rodents: towards translational challenge models for drug discovery in Alzheimer's disease

Babiloni C, Infarinato F, Aujard F, Bastlund JF, Bentivoglio M, Bertini G, Del Percio C, Fabene PF, Forloni G, Herrero Ezquerro MT, Noè FM, Pifferi F, Ros-Bernal F, Christensen DZ, Dix S, Richardson J

Clin Neurophysiol. 2013 Mar;124(3):437-51. doi: 10.1016/j.clinph.2012.07.023. Epub 2012 Oct 4.

A comparison of psychosocial outcomes in elderly Alzheimer caregivers and noncaregivers

Mausbach BT, Chattillion EA, Roepke SK, Patterson TL, Grant I.

Am J Geriatr Psychiatry. 2013 Jan;21(1):5-13. doi: 10.1016/j.jagp.2012.10.001. Epub 2013 Jan 2.

Testosterone effect on brain metabolism in elderly patients with Alzheimer's disease: comparing two cases at different disease stages

Tan RS.

Aging Clin Exp Res. 2013 Jun;25(3):343-7. doi: 10.1007/s40520-013-0049-2. Epub 2013 May 17.

Screening by telephone in the Alzheimer's disease anti-inflammatory prevention trial

Reckess GZ, Brandt J, Luis CA, Zandi P, Martin B, Breitner JC; ADAPT Research Group.

J Alzheimers Dis. 2013;36(3):433-43. doi: 10.3233/JAD-130113.

The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings

Wimo A, Reed CC, Dodel R, Belger M, Jones RW, Happich M, Argimon JM, Bruno G, Novick D, Vellas B, Haro JM.

J Alzheimers Dis. 2013;36(2):385-99. doi: 10.3233/JAD-122392.

Vascular contribution to Alzheimer disease: predictors of rapid progression

Diomedi M, Misaggi G.

CNS Neurol Disord Drug Targets. 2013 Jun;12(4):532-7. doi: 10.2174/1871527311312040015.

Synaptotoxic amyloid-β oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease?

Klein WL.

J Alzheimers Dis. 2013;33 Suppl 1:S49-65. doi: 10.3233/JAD-2012-129039.

Small-molecule inhibitors/modulators of amyloid-β peptide aggregation and toxicity for the treatment of Alzheimer's disease: a patent review (2010 - 2012)

Belluti F, Rampa A, Gobbi S, Bisi A.

Expert Opin Ther Pat. 2013 May;23(5):581-96. doi: 10.1517/13543776.2013.772983. Epub 2013 Feb 21.

Neuropeptides in Alzheimer's disease: from pathophysiological mechanisms to therapeutic opportunities

Van Dam D, Van Dijck A, Janssen L, De Deyn PP.

Curr Alzheimer Res. 2013 Jun;10(5):449-68. doi: 10.2174/1567205011310050001.

Liver X receptors: emerging therapeutic targets for Alzheimer's disease

Sodhi RK, Singh N.

Pharmacol Res. 2013 Jun;72:45-51. doi: 10.1016/j.phrs.2013.03.008. Epub 2013 Mar 28.

Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain

Sultana R, Perluigi M, Butterfield DA.

Free Radic Biol Med. 2013 Sep;62:157-169. doi: 10.1016/j.freeradbiomed.2012.09.027. Epub 2012 Oct 5.

Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications

Sabbagh JJ, Kinney JW, Cummings JL.

Neurobiol Aging. 2013 Jan;34(1):169-83. doi: 10.1016/j.neurobiolaging.2012.02.027. Epub 2012 Apr 1.

Prolonged running, not fluoxetine treatment, increases neurogenesis, but does not alter neuropathology, in the 3xTg mouse model of Alzheimer's disease

Marlatt MW, Potter MC, Bayer TA, van Praag H, Lucassen PJ.

Curr Top Behav Neurosci. 2013;15:313-40. doi: 10.1007/7854_2012_237.